Allogene Therapeutics Inc (NASDAQ:ALLO) price on Wednesday, February 05, rose 1.23% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.64.
A look at the stock’s price movement, the close in the last trading session was $1.62, moving within a range at $1.62 and $1.705. The beta value (5-Year monthly) was 0.836. Turning to its 52-week performance, $5.78 and $1.61 were the 52-week high and 52-week low respectively. Overall, ALLO moved -24.07% over the past month.
Allogene Therapeutics Inc’s market cap currently stands at around $343.86 million, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -50.00% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 30k, representing a -68.42% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ALLO is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend ALLO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ALLO’s current price about -13.88% and -20.42% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.10, while 7-day volatility ratio is 8.69% and 8.32% in the 30-day chart. Further, Allogene Therapeutics Inc (ALLO) has a beta value of 1.05, and an average true range (ATR) of 0.16. Analysts have given the company’s stock an average 52-week price target of $33.5, forecast between a low of $7 and high of $55. Looking at the price targets, the low is -326.83% off current price level while to achieve the yearly target high, price needs to move -3253.66%. Nonetheless, investors will most likely welcome a -1942.68% jump to $33.5 which is the analysts’ median price.
If we refocus on Allogene Therapeutics Inc (NASDAQ:ALLO), historical trading data shows that trading volumes averaged 2.53 over the past 10 days and 2.75 million over the past 3 months. The company’s latest data on shares outstanding shows there are 209.50 million shares.
The 32.88% of Allogene Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 68.51% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 32.35 million on 2025-01-15, giving us a short ratio of 10.45. The data shows that as of 2025-01-15 short interest in Allogene Therapeutics Inc (ALLO) stood at 2170.0001 of shares outstanding, with shares short falling to 32.37 million registered in 2024-12-13. Current price change has pushed the stock -23.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ALLO stock continues to rise going into the next quarter.
